Investment Firm Raises Price Target For Major Biotech Company

Mizuho Boosts MiMedx Group's Price Target to $14, Continues Bullish Outlook.

This article is based on publicly available information and is intended for informational purposes only. It should not be construed as financial or investment advice. Always consult with a certified financial advisor before making any investment decisions.

In a recent move that underscores their confidence in the regenerative medicine sector, Mizuho Secu…